605.52
前日終値:
$607.95
開ける:
$612.98
24時間の取引高:
159.99K
Relative Volume:
0.63
時価総額:
$36.93B
収益:
$2.19B
当期純損益:
$833.04M
株価収益率:
47.64
EPS:
12.71
ネットキャッシュフロー:
$-1.28B
1週間 パフォーマンス:
-0.93%
1か月 パフォーマンス:
-3.11%
6か月 パフォーマンス:
+10.29%
1年 パフォーマンス:
+51.98%
Argen X Se Adr Stock (ARGX) Company Profile
ARGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ARGX
Argen X Se Adr
|
605.52 | 36.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
509.04 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.14 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
280.96 | 36.37B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
250.47 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-17 | アップグレード | Bernstein | Mkt Perform → Outperform |
2025-03-12 | アップグレード | Deutsche Bank | Sell → Hold |
2025-01-17 | ダウングレード | Deutsche Bank | Hold → Sell |
2024-11-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2024-11-05 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
2024-11-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-11-01 | アップグレード | William Blair | Mkt Perform → Outperform |
2024-10-10 | 再開されました | Raymond James | Strong Buy |
2024-10-04 | ダウングレード | Deutsche Bank | Buy → Hold |
2024-08-06 | アップグレード | Barclays | Equal Weight → Overweight |
2024-07-25 | アップグレード | Deutsche Bank | Hold → Buy |
2024-07-23 | アップグレード | Oppenheimer | Perform → Outperform |
2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
2023-12-20 | ダウングレード | Deutsche Bank | Buy → Hold |
2023-12-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
2023-07-31 | 開始されました | Scotiabank | Sector Perform |
2023-07-24 | ダウングレード | UBS | Buy → Neutral |
2023-07-17 | 再開されました | Evercore ISI | Outperform |
2023-06-15 | 開始されました | Societe Generale | Sell |
2023-05-31 | 開始されました | UBS | Buy |
2023-04-25 | 開始されました | Citigroup | Buy |
2023-03-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
2022-12-07 | 開始されました | William Blair | Outperform |
2022-10-12 | 開始されました | Oppenheimer | Perform |
2022-07-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2022-06-28 | 再開されました | Stifel | Buy |
2022-05-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2021-12-08 | 開始されました | Wells Fargo | Overweight |
2021-11-29 | アップグレード | Piper Sandler | Neutral → Overweight |
2021-10-29 | アップグレード | Guggenheim | Neutral → Buy |
2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
2021-10-07 | 開始されました | Jefferies | Buy |
2021-09-23 | アップグレード | Redburn | Neutral → Buy |
2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-07-23 | 開始されました | Deutsche Bank | Hold |
2021-07-19 | 再開されました | Wolfe Research | Outperform |
2021-06-18 | 開始されました | UBS | Buy |
2021-06-04 | 再開されました | Robert W. Baird | Outperform |
2021-05-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
2021-04-23 | 開始されました | Redburn | Neutral |
2021-03-05 | 繰り返されました | H.C. Wainwright | Neutral |
2021-02-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-01-04 | ダウングレード | Guggenheim | Buy → Neutral |
2020-08-25 | 開始されました | Raymond James | Outperform |
2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
2020-07-29 | 開始されました | H.C. Wainwright | Neutral |
2020-02-10 | 開始されました | BofA/Merrill | Buy |
2019-11-05 | 開始されました | Credit Suisse | Neutral |
2019-10-31 | アップグレード | William Blair | Mkt Perform → Outperform |
2019-10-22 | 開始されました | JP Morgan | Overweight |
2019-09-27 | 開始されました | Wells Fargo | Market Perform |
2019-09-16 | 再開されました | Cowen | Outperform |
2019-06-28 | 開始されました | Robert W. Baird | Outperform |
2019-01-18 | 再開されました | SunTrust | Buy |
2019-01-04 | 開始されました | Morgan Stanley | Overweight |
2018-12-17 | 開始されました | Goldman | Buy |
2018-12-14 | 開始されました | Wolfe Research | Outperform |
2018-06-29 | 開始されました | Nomura | Buy |
2018-04-09 | 開始されました | SunTrust | Buy |
2018-01-29 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Argen X Se Adr (ARGX) 最新ニュース
Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa
Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com
Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com
TD Cowen maintains argenx stock with $761 target, bullish outlook - Investing.com India
TD Cowen maintains argenx stock with $761 target, bullish outlook By Investing.com - Investing.com South Africa
Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target - Investing.com
Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target By Investing.com - Investing.com South Africa
Guggenheim raises argenx stock target to $1,100 on growth outlook - Investing.com India
argenx SE ADR to Host Earnings Call - ACCESS Newswire
Argenx Publishes Long-Term Data At The American Academy Of Neurology 2025 Annual Meeting - Marketscreener.com
Argenx Benefits From Multiple Approved Indications of Vyvgart and Strong Uptake - Morningstar
Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says -February 28, 2025 at 11:05 am EST - Marketscreener.com
H.C. Wainwright lifts argenx stock price target to $720 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts argenx stock price target to $720 - Investing.com
Argenx stock target raised to $701 by JMP on VYVGART strength - Investing.com South Africa
Argenx stock target lifted to $761 by TD Cowen, maintains buy - Investing.com India
Argenx’s VYVGART Franchise Drives Strong Performance and Growth Prospects - TipRanks
argenx ADR earnings beat by $10.57, revenue topped estimates - Investing.com South Africa
Argenx Q4 Swings to Earnings, Operating Income Increases -February 27, 2025 at 04:00 am EST - Marketscreener.com
Immunology Company argenx Swings to Profit in FY24; Net Sales Climb -February 27, 2025 at 01:24 am EST - Marketscreener.com
Argenx: $737 Million In Q4 Global Product Net Sales -February 27, 2025 at 01:14 am EST - Marketscreener.com
Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs - Investor's Business Daily
BBVA Argentina ADR (BBAR) Shares Rise Despite Market Challenges - The News Heater
Telecom Argentina S.A. ADR (TEO) Stock Records 32.38% Quarterly Movement - The News Heater
Guru Fundamental Report for ARGXBenjamin Graham - Nasdaq
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
argenx SE : The stock is approaching a major resistance level -January 29, 2025 at 04:11 am EST - Marketscreener.com
argenx's SWOT analysis: biotech stock soars on VYVGART success, pipeline promise - Investing.com India
Argenx stock price target raised to $717 by H.C. Wainwright - Investing.com India
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Truist Securities raises argenx stock rating to Buy, says will exceed Vision 2030 - Investing.com
Jefferies raises argenx stock target, reaffirms buy on global sales result - Investing.com
argenx's SWOT analysis: biotech stock soars on vyvgart success - Investing.com
Piper Sandler increases argenx stock price target on revised estimates - Investing.com
Argenx stock soars to all-time high of $645.31 amid robust growth - Investing.com
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
Argenx stock soars to all-time high of $630.4 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $630.4 amid robust growth - Investing.com
argenx's SWOT analysis: biotech stock soars on VYVGART success - Investing.com
Argen X Se Adr (ARGX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):